Anhui Sunhere Pharmaceutical Excipients Co Ltd

Anhui Shanhe Pharmaceutical Excipients Co., Ltd. signed a state-owned construction land use right transfer contract with the Huainan Municipal Natural Resources and Planning Bureau on September 9, 2026, acquiring an industrial land parcel in the Huainan Economic Development Zone for a total land price of 24.4087 million yuan. The parcel, numbered HGTG26022, covers 73,965.74 square meters, is designated as Class III industrial land, and has a transfer term of 50 years. As of the announcement date, the company has paid all amounts in full and obtained the real estate title certificate. The matter was approved at the 12th meeting of the company's sixth board of directors on August 21, 2026. The acquired land will be used for a high-end excipient intelligent manufacturing base project, funded by the company's own capital. The company stated that this land acquisition will not affect its business independence or financial condition, and is not expected to have a significant impact on performance in the short term.

Shanhe Pharmaceutical Excipients released its 2026 half-year report. First-half operating revenue was 522 million yuan, up 10.8% year on year. Net profit attributable to the parent was 96.19 million yuan, up 3.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 86.71 million yuan, up 2.3% year on year. Net operating cash flow was 91.01 million yuan, up 13.4% year on year. Second-quarter operating revenue was 260 million yuan, up 16.7% year on year. Net profit attributable to the parent was 49.13 million yuan, up 7.1% year on year. As of the end of the second quarter, total assets were 1.788 billion yuan, up 4.4% from the end of the previous year. Net assets attributable to the parent were 1.035 billion yuan, up 2.8% from the end of the previous year. The company said its business operations had not changed significantly, and it continued to focus on the research, production and sales of pharmaceutical excipients, while advancing the construction of a high-end excipients intelligent manufacturing base project.